{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.3"},{"groupId":"OG001","value":"35.5"},{"groupId":"OG002","value":"39.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"454"},{"groupId":"OG001","value":"389"},{"groupId":"OG002","value":"354"}],"units":"Participants"}],"description":"Percentage of participants with atezolizumab-specific Adverse Events of Special Interest (AESIs) Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0.","groups":[{"description":"Participants received blinded atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).","id":"OG000","title":"Atezolizumab+Gemcitabine+Carboplatin/Cisplatin"},{"description":"Participants received blinded placebo matched to atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).","id":"OG001","title":"Placebo+Gemcitabine+Carboplatin/Cisplatin"},{"description":"Eligible participants received open-label atezolizumab as monotherapy.","id":"OG002","title":"Atezolizumab Monotherapy"}],"paramType":"NUMBER","populationDescription":"The safety population was defined as participants who received any amount of any component of study treatment. Participants were analyzed according to the treatment received.","reportingStatus":"POSTED","timeFrame":"Baseline up to 93 months","title":"Percentage of Participants With Atezolizumab-Specific Adverse Events of Special Interest (AESIs)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}